Loading…
IPHA
Innate Pharma SA
NASDAQ· Healthcare· Biotechnology· CUSIP 45781K204
$2.22-0.45%Price as of Aug 29, 18:40 UTC · updated once a day, after the close
Key metrics
- Market cap
- $247.97M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.64
- ROE
- —
- Profit margin
- 0.00%
- Revenue growth
- -46.70%
- Beta
- 0.86
- 52-week high
- $2.71
- 52-week low
- $1.17
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -70.7% over 5Y.
today you would have $275.53▼ -72.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.75 | $1.84 | $2.80 | $3.73 | |
| P/S | 9.1x | 58.8x | 12.2x | 4.4x | 6.0x |
| P/B | 5.5x | — | 17.5x | 4.4x | 5.5x |
| EPS | -$0.55 | -$0.61 | -$0.09 | -$0.73 | |
| Profit margin | -254.58% | -1764.51% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ADAGAdagene Inc. | $3.68 | — | 2.8x | — | -28.50% | $247.09M |
| SIONSionna Therapeutics, Inc. | $5.51 | — | 0.9x | — | -32.34% | $249.12M |
| PROFProfound Medical Corp. | $6.85 | — | 4.2x | — | -73.53% | $250.25M |
| NGENNervgen Pharma Corp | $2.28 |
About the company
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
- 164
- Marseille, France
Company description provided by Yahoo Finance.